Abstract
Clinical observations support the postulate that chronic low-grade inflammation underlies metabolic diseases and inflammatory mediators can trigger some metabolic diseases. In disorder condition, what is the first one: metabolic diseases cause inflammation or conversely? This “chicken or egg” type question was hard to answer. However, instead of focusing on this difficult issue, we should ask another challenging question: what are the links between inflammation and metabolic diseases? Seizing the key from this chaos may be the best way to solve the problem and break the cycle. To answer this question, we review the regulators (such as NF-κB, PPARs, mTOR, and STAT3) that have important roles in both metabolism and inflammation. These “bridge proteins” that link metabolic diseases and inflammation not only increase our understanding of these two diseases, but also provide potential targets for therapeutics and practical clinical applications.
Keywords: Inflammation, metabolic disease, NF-κB, PPARs, mTOR, STAT3.
Graphical Abstract
Current Protein & Peptide Science
Title:“Bridge Proteins” Link Inflammation and Metabolic Diseases: Potential Targets for Therapeutics
Volume: 18 Issue: 6
Author(s): Hailong Jiang, Guixin Qin, Xuefeng Zhang and Dongsheng Che*
Affiliation:
- Key Laboratory of Animal Production, Product Quality and Security, Ministry of Education, Jilin Agricultural University, Changchun 130118,China
Keywords: Inflammation, metabolic disease, NF-κB, PPARs, mTOR, STAT3.
Abstract: Clinical observations support the postulate that chronic low-grade inflammation underlies metabolic diseases and inflammatory mediators can trigger some metabolic diseases. In disorder condition, what is the first one: metabolic diseases cause inflammation or conversely? This “chicken or egg” type question was hard to answer. However, instead of focusing on this difficult issue, we should ask another challenging question: what are the links between inflammation and metabolic diseases? Seizing the key from this chaos may be the best way to solve the problem and break the cycle. To answer this question, we review the regulators (such as NF-κB, PPARs, mTOR, and STAT3) that have important roles in both metabolism and inflammation. These “bridge proteins” that link metabolic diseases and inflammation not only increase our understanding of these two diseases, but also provide potential targets for therapeutics and practical clinical applications.
Export Options
About this article
Cite this article as:
Jiang Hailong, Qin Guixin, Zhang Xuefeng and Che Dongsheng*, “Bridge Proteins” Link Inflammation and Metabolic Diseases: Potential Targets for Therapeutics, Current Protein & Peptide Science 2017; 18 (6) . https://dx.doi.org/10.2174/1389203717666160627081207
DOI https://dx.doi.org/10.2174/1389203717666160627081207 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis & Characterization of 2-(substituted-phenyl)acetohydrazide Analogs, 1,3,4-oxadiazoles, and 1,2,4-triazine Ring Systems: A Novel Class of Potential Analgesic and Anti-Inflammatory Agents
Letters in Drug Design & Discovery Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Pleiotropic Effects of ARB in Vascular Metabolism - Focusing on Atherosclerosis-Based Cardiovascular Disease
Current Vascular Pharmacology Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Management of Cardiogenic Shock due to Thyrotoxicosis: A Systematic Literature Review
Current Cardiology Reviews Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Biomarkers Associated with Atrial Fibrosis and Remodeling
Current Medicinal Chemistry Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Chemical Diversity of Bioactive Marine Natural Products: An Illustrative Case Study
Current Medicinal Chemistry